|
|
|
| home > white papers > Speciality Logistics Outlook 2015 - World Courier |
|
|
 WHITE PAPERS |
|
World Courier
|
|
Speciality Logistics Outlook 2015
|
|
To date, there are more than 178,000 registered clinical trials taking
place across the globe, and global pharma’s volume has more than doubled
over the last decade. With emerging markets showing explosive
predictive growth through 2016, shippers and trial sponsors can expect
continued regulatory and overall logistics complexities that foster
demand for local, inmarket resources across the globe.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Sanofi announced today an equity investment of $180 million and a new
strategic collaboration with Owkin comprised of discovery and
development programmes in four exclusive types of cancer, with a total
payment of $90 million for three years plus additional research
milestone-based payments.
More info >> |
|
 |
White Papers |
 |
|
Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies
PCI Pharma Services
Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >> |
|
|
|
